论文部分内容阅读
docetaxel（商品名Taxotere）是一种新的半合成的紫杉醇类衍生物，其促进微管蛋白装配和抑制微管解聚的能力为紫杉醇的2倍。在临床前试验中docetaxel的细胞毒作用等于或大于紫杉醇。在1期临床试验中，docetaxel对卵巢癌患者有明显的抗癌效果，因此进行！期临床试验以评定该化合
Docetaxel (trade name Taxotere) is a new semisynthetic paclitaxel derivative with twice the ability to promote tubulin assembly and inhibit microtubule depolymerization as paclitaxel. The docetaxel cytotoxicity is equal to or greater than paclitaxel in preclinical trials. In Phase 1 clinical trials, docetaxel has a significant anti-cancer effect on ovarian cancer patients, so proceed! Phase of clinical trials to assess the compound